As we face the difficulty of coping with this virus, government, people and pharma companies have had more than enough.
Just recently on the 20th of June, in the Time of India newspaper, it was said that a major drug firm called Glenmark Pharmaceuticals released a new drug called Favipiravir under the brand name Fabiflu. It was made for COVID patients that are in mild to moderate conditions and costs about Rs.103
This the first oral approved medication in India for the treatment of COVID 19 and has shown promising results in Japan, Italy and China and has been approved for treatment in Russia. Global clinical trials have already started on more than 3000 people already, in India, the US, Canada, Italy, China, France, the UK and many other countries the company said.
India’s very own drug regulator decided that this medication fell under “restricted emergency authorisation” so that the approval process would become much faster and so that the infected people could have access to it, although it can only be used in cases of emergency or a health crisis and every patient must have a signed and informed consent before taking it.
Even though this drug may be as effective as the people say they are, we don’t know about the side effects this drug may or may not have, but as we see the cases in India increasing every day, this is a good way to move forward and help the people to work this virus out of their lives.
Writer: Anaya Parekh
24/06/2020
Kommentarer